Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

A Multifaceted Approach to Managing Cancer-Related Anxiety and Depression

August 27, 2025
By Boris M. Kiselev, MD
News
Video

Boris M. Kiselev, MD, explores evidence-based interventions for managing cancer-related anxiety and depression.

When addressing the psychological distress that often accompanies a cancer diagnosis, it is crucial for clinicians to consider a comprehensive toolkit that extends beyond conventional psychiatric medications.

While antidepressants and other pharmacological agents have a well-established role and are recommended by clinical guidelines, a truly holistic approach integrates a variety of evidence-based interventions. Boris M. Kiselev, MD, delves into the most effective methods for managing cancer-related anxiety and depression, highlighting the importance of psychotherapy as a foundational and lasting tool. He also discusses the significant benefits of integrative therapies and the critical need to address underlying medical conditions, offering a nuanced perspective on providing compassionate and effective care.

Kiselev is a consult liaison psychiatrist at Atrium Health Carolinas Medical Center, an assistant professor of the Psycho-Oncology Program in the Department of Supportive Oncology at Atrium Health Levine Cancer Institute, and an assistant professor in Internal Medicine.

Transcript:

[Many] times when people think about psycho-oncology, they’re thinking about antidepressants and what other things are out there. The idea that even though antidepressants are helpful and there’s a good evidence base to support their use for anxiety, depression, and cancer, and their use is recommended by guidelines, we still want to make sure we are using all the tools available to us. Psychology guidelines do recommend considering things like mindfulness-based interventions. This includes things like mindfulness-based stress reduction when that’s administered in a group or individual setting that has good, randomized trials supporting efficacy for anxiety and depression in patients dealing with cancer. There’s also good evidence for things like music therapy, relaxation interventions, for moderate quality evidence. There’s also good evidence for exercise being helpful for patients dealing with cancer, and that not only helps with both anxiety and depression, but also with sleep and fatigue. That’s supported by the American College of Sports Medicine Physical Activity Guidelines for adults dealing with cancer.

Additionally, there’s other integrative approaches too. You can consider things like Tai Chi, acupuncture, those all have lower quality evidence, but have been studied. Here at [Levine Cancer Institute], where I work, we have a robust integrative oncology department, and we’re often coordinating with them, referring patients to them, to get them connected with those types of treatment.

Other things to think about when managing these symptoms for patients, especially for those who are working in oncology is to make sure that we’re thinking about their medical comorbidities. For instance, thinking about patients who [receive] immunotherapy, considering endocrinopathies, it could be contributing to their psychiatric symptoms, or thinking about sleep disorders.

In terms of interventions, another thing I want to make sure I talk about as well is psychotherapy, and so the idea is that that’s going to help in many ways when we’re dealing with cancer, to process their experience. Talking about processing grief, learning tools and techniques can help them manage the symptoms day to day, develop coping skills, and help them to get just gain insight into themselves. The great thing about psychotherapy is that even after they complete the psychotherapy treatment that they’re doing, they’ll have those tools that they can take with them afterwards that will continue to be helpful to them in a longitudinal way.

Recent Videos
Experts weigh in on tumor-informed testing, false positives, relevant trial data, and other key concepts related to circulating tumor DNA.
Hydration and a healthy, well-balanced diet may mitigate fatigue among patients undergoing treatment for cancer.
Bland foods, such as crackers and chicken noodle soup, as well as fluids with electrolytes, may help stave off treatment-related nausea.
According to Denise B. Reynolds, RD, patients eating well should not be experiencing nutritional deficiencies during cancer treatment.
Related Content
Advertisement

Black patients experienced lower survival rates across cancer types and several categories of urbanicity, particularly in breast and colorectal cancers.

Five-Year Cancer Survival Rates Lower Among Rural Cancer Populations

Roman Fabbricatore
September 25th 2025
Article

Black patients experienced lower survival rates across cancer types and several categories of urbanicity, particularly in breast and colorectal cancers.


Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

Diving Into the Practical Applications of ctDNA in Oncology Care

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Arnab Basu, MBBS, MPH, FACP
September 25th 2025
Podcast

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.


Greater regulatory and policy clarity may better optimize clinician use of artificial intelligence in treating patients with cancer.

Advancing AI in Oncology: Critical Considerations for Clinical Practice

Roman Fabbricatore
September 19th 2025
Article

Greater regulatory and policy clarity may better optimize clinician use of artificial intelligence in treating patients with cancer.


How to Discuss Death: A Conversation of Mortality in Cancer Care

How to Discuss Death: A Conversation of Mortality in Cancer Care

Daniel C. McFarland, DO;William Breitbart, MD
September 22nd 2025
Podcast

Daniel C. McFarland, DO; and guest William S. Breitbart, MD, discuss the critical role of meaning-centered therapy in addressing the psychosocial needs of patients with cancer.


Clinical benefit with the investigational agent was reported among 48% of patients with solid tumors at or above the therapeutic dose threshold.

LP-184 Shows Favorable Safety, Pharmacokinetics in Advanced Solid Tumors

Roman Fabbricatore
September 17th 2025
Article

Clinical benefit with the investigational agent was reported among 48% of patients with solid tumors at or above the therapeutic dose threshold.


Rezatapopt Yields Responses Across TP53 Y220C-Mutated Solid Tumor Types

Rezatapopt Yields Responses Across TP53 Y220C-Mutated Solid Tumor Types

Tim Cortese
September 10th 2025
Article

Rezatapopt achieved an ORR of 33% in all patients, and an ORR of 43% in patients with ovarian cancer, with 1 confirmed complete response.

Related Content
Advertisement

Black patients experienced lower survival rates across cancer types and several categories of urbanicity, particularly in breast and colorectal cancers.

Five-Year Cancer Survival Rates Lower Among Rural Cancer Populations

Roman Fabbricatore
September 25th 2025
Article

Black patients experienced lower survival rates across cancer types and several categories of urbanicity, particularly in breast and colorectal cancers.


Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

Diving Into the Practical Applications of ctDNA in Oncology Care

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Arnab Basu, MBBS, MPH, FACP
September 25th 2025
Podcast

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.


Greater regulatory and policy clarity may better optimize clinician use of artificial intelligence in treating patients with cancer.

Advancing AI in Oncology: Critical Considerations for Clinical Practice

Roman Fabbricatore
September 19th 2025
Article

Greater regulatory and policy clarity may better optimize clinician use of artificial intelligence in treating patients with cancer.


How to Discuss Death: A Conversation of Mortality in Cancer Care

How to Discuss Death: A Conversation of Mortality in Cancer Care

Daniel C. McFarland, DO;William Breitbart, MD
September 22nd 2025
Podcast

Daniel C. McFarland, DO; and guest William S. Breitbart, MD, discuss the critical role of meaning-centered therapy in addressing the psychosocial needs of patients with cancer.


Clinical benefit with the investigational agent was reported among 48% of patients with solid tumors at or above the therapeutic dose threshold.

LP-184 Shows Favorable Safety, Pharmacokinetics in Advanced Solid Tumors

Roman Fabbricatore
September 17th 2025
Article

Clinical benefit with the investigational agent was reported among 48% of patients with solid tumors at or above the therapeutic dose threshold.


Rezatapopt Yields Responses Across TP53 Y220C-Mutated Solid Tumor Types

Rezatapopt Yields Responses Across TP53 Y220C-Mutated Solid Tumor Types

Tim Cortese
September 10th 2025
Article

Rezatapopt achieved an ORR of 33% in all patients, and an ORR of 43% in patients with ovarian cancer, with 1 confirmed complete response.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.